Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Roussel
CLAFORAN 500 mg Vial CLAFORAN 1 g Vial SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form) CLAFORAN 500 mg Vial CLAFORAN 1 g Vial COMPOSITION: Cefotaxime is a semi-synthetic cephalosporin chemically-designated as 3-acetoxymethyl-7/(2-(2-amino-4- thiazolyl)-2- methoxyimino-acetyl)-amino/-ceph-3-eme-4-carboxylic acid, sodium salt. Each vial of powder contains either:- a. cefotaxime sodium 524 mg corresponding to 500 mg cefotaxime base or b. cefotaxime sodium 1,048 g corresponding to 1 g cefotaxime base PHARMACOLOGICAL CLASSIFICATION: A. 20.1.1, Broad spectrum antibiotics PHARMACOLOGICAL ACTION: Claforan is a semi-synthetic cephalosporin antibiotic with a broad spectrum of activity against both Gram positive and Gram negative bacteria. Claforan is bactericidal in its mode of action and has a high degree of stability in the presence of ß-lactamases. The following have been found to be sensitive to Claforan in vitro : Gram positive: Staphylococcus aureus, including certain penicillinase and non-penicillinase producing strains, Staphylococcus epidermidis, Streptococcus pyogenes (Group A ß-haemolytic streptococci), Streptococcus agalactiae (Group B streptococci) (Note: most strains of enterococci, eg, S.faecalis are resistant), Streptococcus pneumoniae. Gram negative: Citrobacter species, Enterobacter species, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant H influenzae), Klebsiella species (including K pneumoniae), Neisseria gonorrhoeae, Proteus mirabilis, Morganella (Proteus) morganii, Proteus rettgeri, Proteus vulgaris, Providencia species, Salmonella species, (including S. typhi), Serratia species, Shigella species. Cefotaxime and aminoglycosides have been shown to be synergistic in vitro against some strains of P. aeruginosa. Anaerobes: Bacteroides species, Clostridium species (Note Lue koko asiakirja